Last reviewed · How we verify

Budesonide/formoterol and tiotropium — Competitive Intelligence Brief

Budesonide/formoterol and tiotropium (Budesonide/formoterol and tiotropium) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist. Area: Respiratory/Pulmonology.

marketed Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Budesonide/formoterol and tiotropium (Budesonide/formoterol and tiotropium) — Brian J Lipworth. This combination reduces airway inflammation and constriction by combining a corticosteroid with two bronchodilators that work through different pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Budesonide/formoterol and tiotropium TARGET Budesonide/formoterol and tiotropium Brian J Lipworth marketed Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Trimbow pMDI Trimbow pMDI Medicines Evaluation Unit Ltd marketed Triple combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
BFF MDI (PT009) BFF MDI (PT009) Pearl Therapeutics, Inc. phase 3 Triple combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium Chiesi Farmaceutici S.p.A. phase 3 Inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
BDP/FF/GB BDP/FF/GB Chiesi Farmaceutici S.p.A. phase 3 Triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Chiesi Farmaceutici S.p.A. phase 3 Triple-combination inhaler (ICS/LABA/LAMA) Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor
CHF 5993 100/6/12.5 µg CHF 5993 100/6/12.5 µg Chiesi Farmaceutici S.p.A. phase 3 ICS/LABA/LAMA combination Glucocorticoid receptor, beta-2 adrenergic receptor, muscarinic M3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist class)

  1. Brian J Lipworth · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budesonide/formoterol and tiotropium — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-formoterol-and-tiotropium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: